Fertility & pregnancy Pregnancy Motherhood News

Memora Health partners with PeriGen to improve maternal and infant care

By Published On: December 15, 2022
Memora Health partners with PeriGen to improve maternal and infant care

The digital healthcare platform Memora Health has partnered with a US perinatal decision support software to advance innovation in maternal and infant care.

The partnership with PeriGen is the first of its kind looking to offer health systems the ability to use technology to monitor and engage obstetrics patients from labour and delivery through the postpartum period at home.

The company says the collaboration will combine a labour and delivery inpatient solution with a post-discharge monitoring tool for those same patients, which have traditionally been separate offerings.

The coordinated solution for women’s health will be made available to health systems nationally.

“Health systems offering robust maternal and foetal monitoring that supports new families during labour and throughout their transition home can gain tremendous lifetime loyalty from these investments,” said Manav Sevak, co-founder and CEO of Memora Health.

“We’re excited to partner with PeriGen to offer this innovative solution that can help health systems continue to use their digital assets as a key strategic lever to remain competitive in a challenging market.”

Matthew Sappern, CEO of PeriGen, said: “In recent years, the US has witnessed a considerable rise in maternal morbidity and mortality – much of which is preventable.

“This is a complex, multifactorial challenge and applying technology to standardise and control modifiable factors is an absolute necessity to improvement. Both PeriGen and Memora are expert at this and the combination promises to be powerful.”

PeriGen’s platform aims to consolidate and summarise labour and delivery data to promote better human recognition and communication about impending problems during labour.

The two companies say the partnership will help them enable clinicians to spend more time on direct patient care and less time in front of screens, to promote the best outcomes for mothers and their babies.

Boston start-up welcomes validation of tumour gangliosides as diagnostic markers for ovarian cancer detection
Nottingham fertility group to expand to the US and Spain